Equities Analysts Issue Forecasts for SPRY FY2025 Earnings

Key Points

• Analysts at Cantor Fitzgerald lowered ARS Pharmaceuticals' FY2025 earnings per share estimate from ($1.44) to ($1.92), while the consensus estimate for the current full-year earnings is ($0.55) per share.
• Wall Street Zen downgraded the stock's rating from "hold" to "sell", with an average target price of $31.00 and mixed ratings from various analysts.
• ARS Pharmaceuticals' latest quarterly earnings missed estimates by ($0.05), reporting ($0.46) per share, while revenues exceeded projections at $15.72 million.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for ARS Pharmaceuticals in a report released on Thursday, August 14th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will earn ($1.92) per share for the year, down from their previous forecast of ($1.44). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. Cantor Fitzgerald also issued estimates for ARS Pharmaceuticals' FY2026 earnings at ($1.01) EPS.

Separately, Wall Street Zen cut ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, July 26th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.00.

ARS Pharmaceuticals Trading Up 0.4%

Shares of NASDAQ SPRY opened at $14.53 on Monday. The stock's 50 day moving average price is $16.85 and its two-hundred day moving average price is $14.32. ARS Pharmaceuticals has a 52-week low of $10.00 and a 52-week high of $18.90. The stock has a market capitalization of $1.44 billion, a P/E ratio of -29.65 and a beta of 0.90. The company has a quick ratio of 5.98, a current ratio of 6.17 and a debt-to-equity ratio of 0.37.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.05). ARS Pharmaceuticals had a negative net margin of 42.74% and a negative return on equity of 21.85%. The firm had revenue of $15.72 million for the quarter, compared to analyst estimates of $12.92 million.

Insider Activity

In other news, Director Brent L. Saunders sold 120,000 shares of the firm's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $14.25, for a total transaction of $1,710,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander A. Fitzpatrick sold 102,969 shares of the firm's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total value of $1,451,862.90. Following the sale, the insider directly owned 89,613 shares of the company's stock, valued at approximately $1,263,543.30. This represents a 53.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,043,118 shares of company stock worth $18,024,863 in the last quarter. 33.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ARS Pharmaceuticals

Large investors have recently modified their holdings of the stock. Bernard Wealth Management Corp. bought a new stake in shares of ARS Pharmaceuticals during the 4th quarter worth $27,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of ARS Pharmaceuticals in the first quarter valued at $37,000. GAMMA Investing LLC lifted its holdings in shares of ARS Pharmaceuticals by 4,319.7% in the first quarter. GAMMA Investing LLC now owns 3,359 shares of the company's stock valued at $420,000 after purchasing an additional 3,283 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of ARS Pharmaceuticals by 78,100.0% in the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company's stock valued at $49,000 after purchasing an additional 3,905 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of ARS Pharmaceuticals by 16.1% in the second quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company's stock valued at $98,000 after purchasing an additional 777 shares in the last quarter. 68.16% of the stock is owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.